A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The recommendation makes a second drug available in England for treating transthyretin amyloidosis with cardiomyopathy.

The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

The firms will use the funds to integrate FYR's liquid biopsy platform in NuvOx's Phase II trial evaluating the oxygen therapeutic NanO₂ as a radiosensitizer.

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

The agency considered clinical trial data showing Redemplo can significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome versus placebo.

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.